Vesalius Biocapital I
Vesalius Biocapital Partners S.à r.l., founded in 2007 and based in Strassen, Luxembourg, is a venture capital and private equity firm focused on investing in life sciences and health-related companies at various stages of development. The firm targets sectors such as healthcare, pharmaceuticals, therapeutics, medtech, biotechnology, and nanotechnology, with an emphasis on developing novel drugs, medical devices, diagnostics, and innovative nutrition technologies aimed at addressing unmet medical needs. Vesalius Biocapital typically invests between €1 million and €5 million, with the potential for up to €10 million across multiple financing rounds, primarily in companies located in Europe, particularly in the Benelux countries and German-speaking regions. The firm often leads or co-leads investment syndicates and actively participates in its portfolio companies by taking board seats. With over €150 million under management across two funds, Vesalius Biocapital has successfully contributed to the growth of around 20 companies since its inception.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.